Bothell, Wa., USA - March 24, 2010, Bothell, Wa., USA - OncoGenex Pharmaceuticals, Inc. announced that the Company has appointed Jack Goldstein and H. Stewart Parker to its board of directors.
Article continues below
Dr. Goldstein joins the board as chairman. He served as president and chief operating officer of Chiron Corporation until its acquisition by Novartis in April 2006. Before Chiron, he spent two years as a general partner at Windamere Venture Partners preceded by four years at Applied Imaging Corporation, first as president and chief executive officer and later as chairman.
Dr. Goldstein spent over a decade at Ortho Diagnostic Systems, a Johnson & Johnson company, in various executive positions including four years as president. Earlier, he was vice president of research and development at a division of Baxter Healthcare Corporation.
Dr. Goldstein earned a bachelor of art degree in biology from Rider University, a Master of Science degree in immunology, and doctorate in microbiology from St. John's University. He sits on the board of directors of Illumina, Inc. and Orasure Technologies Inc.
Ms. Stewart Parker served as president, chief executive officer and director of Targeted Genetics Corporation, a position she held since managing its formation and spinout from Immunex Corporation in 1992 (Immunex was subsequently acquired by Amgen). Prior to Targeted Genetics, she served in various capacities at Immunex for ten years, most recently as vice president, corporate development.
Ms. Stewart Parker also served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry, and as a director of privately held and publicly held companies.
Ms. Stewart Parker received her B.A. and M.B.A. from the University of Washington.
In addition, Dr. Martin Mattingly has agreed to stand for election at the Company's upcoming Annual General Meeting.
Mr. Mattingly, Pharm.D., is the chief executive officer and member of the board of directors of Trimeris, Inc. He most recently served as president and chief executive officer at Ambrx, Inc. Prior to that, he served as executive vice president and chief operating officer at CancerVax.
He also previously provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc. These assignments included general manager of the Agouron HIV division; vice president, product development group at Pfizer; and vice president, global marketing planning at Pfizer. ■
New York Governor Kathy Hochul announced that AgriAmerica Fruit Products has completed the revitalization and upgrade of a 69,000-square-foot grape juice processing facility located at 200 Water Street in the Village of Fredonia.